Heron Therapeutics Management
Management criteria checks 1/4
Heron Therapeutics' CEO is Craig Collard, appointed in Apr 2023, has a tenure of 2.67 years. total yearly compensation is $3.40M, comprised of 19.7% salary and 80.3% bonuses, including company stock and options. directly owns 0.29% of the company’s shares, worth $685.28K. The average tenure of the management team and the board of directors is 1.9 years and 2.8 years respectively.
Key information
Craig Collard
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 19.72% |
| CEO tenure | 2.7yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.9yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target
Nov 08
Heron Therapeutics: The View From 30,000 Feet Amid The Zynrelef Launch
Aug 25Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 09
ZYNRELEF Label Expansion And VAN Launch Will Broaden Medical Access
Expansion of ZYNRELEF labeling and VAN launch enhance market potential, operational efficiency, and revenue growth.Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop
Apr 18Heron Therapeutics: Four Horse Race Of Approved Therapies
Mar 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry
Mar 01Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Nov 13Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Aug 08Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$14m |
| Jun 30 2025 | n/a | n/a | -US$931k |
| Mar 31 2025 | n/a | n/a | -US$8m |
| Dec 31 2024 | US$3m | US$670k | -US$14m |
| Sep 30 2024 | n/a | n/a | -US$28m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$81m |
| Dec 31 2023 | US$11m | US$488k | -US$111m |
Compensation vs Market: Craig's total compensation ($USD3.40M) is above average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.
CEO
Craig Collard (59 yo)
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.7yrs | US$3.40m | 0.29% $ 685.3k | |
| Executive VP & CFO | 2.5yrs | US$1.42m | 0.098% $ 235.5k | |
| Executive VP & Chief Development Officer | 2.5yrs | US$1.54m | 0.091% $ 217.7k | |
| Executive VP & COO | less than a year | no data | no data | |
| Executive Director of Legal | less than a year | no data | no data | |
| Vice President of Marketing | 2.3yrs | no data | no data | |
| Executive Director of People Management & Training | less than a year | no data | no data | |
| Senior Vice President of Manufacturing & Supply | less than a year | no data | no data | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 2.9yrs | no data | no data | |
| Chief Business Officer | 1.3yrs | no data | no data | |
| Senior Vice President of Medical Affairs Strategy & Engagement | 1.9yrs | no data | no data | |
| Executive Director | no data | no data | no data |
Experienced Management: HRTX's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$3.40m | 0.29% $ 685.3k | |
| Independent Director | 11.9yrs | US$160.00k | 0.036% $ 86.2k | |
| Independent Director | 9.5yrs | US$155.63k | 0.036% $ 86.7k | |
| Independent Director | 1.1yrs | US$323.91k | 0.0013% $ 3.1k | |
| Independent Chairman | 2.8yrs | US$166.25k | 0.019% $ 46.2k | |
| Independent Director | 4.3yrs | US$152.50k | 0.037% $ 89.7k | |
| Director | less than a year | no data | no data |
Experienced Board: HRTX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/07 19:13 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Heron Therapeutics, Inc. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Joshua Schimmer | Evercore ISI |